华兰生物：参股公司收到药品注册临床试验受理通知书

Core Viewpoint - The company announced that its affiliate, Hualan Gene Engineering Co., Ltd., has received the acceptance notice for the clinical trial application for the domestic production of Pembrolizumab injection from the National Medical Products Administration [1] Group 1 - The drug name is Pembrolizumab injection, classified as a therapeutic biological product of category 3.3 [1] - The specification of the drug is 100mg (4ml) per bottle [1] - The indications for the drug include melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [1]